Following up on the rumours I posted about yesterday regarding a potential bid by the FDA to choke of direct-to-consumer genetic testing companies' supply of genotyping chips, I received the following statement by email from 23andMe's PR firm:
23andMe is engaged in an ongoing process with the FDA.
23andMe understands that Illumina is also engaged in such a process.
23andMe has no reason to believe there will be an interruption in the supply of Illumina chips at this time.
I understand we'll have some more clarity on this issue from the FDA tomorrow.
- Log in to post comments
I guess the FDA don't do clarity. This story does not look like it is over yet, see Mary Carmichael
What the heck? The FDA doesn't take costs into account? Huh?
How are we supposed to control costs in healthcare then?
If this is an 'agency wide' policy this is a serious issue and much bigger than DTC.
Their clarification is also clear as mud
So...they are relying on a creative interpretation of the law which allows them to vastly expand their authority to cover thousands upon thousands of clinical labs without actually going through any kind of formal rulemaking process, or doing even the most BASIC evaluation of costs and benefits!
Forget about DTC...someone get CAP, ACLA, AMP, ACMG on the horn, because this sure looks like the basis for a class action lawsuit.